podcast 293: her2-“low” breast cancer and its reponse to an antibody-drug conjugate
Published 3 months ago • 43 plays • Length 11:25Download video MP4
Download video MP3
Similar videos
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
54:43
the science of her2-low breast cancer and implications for the pathology team
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
6:51
adcs for her2 and her2-low breast cancer
-
5:16
treatment options for her2-low breast cancer: all you need to know
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
2:21
adcs for the treatment of her2-low breast cancer
-
1:23
antibody-drug conjugates for the treatment of breast cancer
-
1:53:20
44- her2 positive disease
-
0:31
remaining questions regarding her2-low breast cancer
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
2:00
ribociclib in early breast cancer | nejm
-
10:21
novel antibody-drug conjugates (adcs) technologies for management of mbc
-
6:46
updates on her2-low breast cancer
-
2:43
study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer
-
1:35
advances in novel adcs for her2-expressing breast cancer
-
51:38
medical update: her2-positive and triple-positive metastatic breast cancer